Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neurexophilin 2 is a cysteine-rich, N-glycosylated secreted glycoprotein with an N-terminal signal peptide, expressed mainly in a scattered subpopulation of neurons within the brain. It binds tightly to the extracellular domains of alpha-neurexins, likely serving as a ligand in neuronal signaling pathways. The protein undergoes several post-translational modifications, including glycosylation, and appears to be brain-specific with a possible role in modulating synaptic communication. Its gene shows species-selective expression, being prominent in cattle but not rodents. Although not a receptor or enzyme, its interaction with cell-surface proteins suggests involvement in synaptic regulation and neuropeptide signaling pathways. NXPH2 is not currently a direct therapeutic target, and there are no drugs or established biomarkers associated with it; however, its presence is linked (via genetic association studies) to certain developmental and nephrological diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neurexophilin 2 (NXPH2).